<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01330277</url>
  </required_header>
  <id_info>
    <org_study_id>BH03/2011</org_study_id>
    <nct_id>NCT01330277</nct_id>
  </id_info>
  <brief_title>Biomarker for Hunter Disease</brief_title>
  <acronym>BioHunt</acronym>
  <official_title>Biomarker for Hunter Disease an International, Multicenter, Epidemiological Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rostock</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centogene AG Rostock</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rostock</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hunter Syndrome (mucopolysaccharidosis II [MPS II]) is a lysosomal storage disorder caused by
      reduction or absence of the iduronate-2-sulphatase enzyme has still the problem of the
      difficulties of a simple and reliable analysis for the primary diagnosis but also for the
      follow-up of the disease. Especially in the cases of female carriers which have been reported
      to have some symptoms of MPS II due to skewed X-inactivation makes the diagnosis complex.
      However, early diagnosis and treatment of disease complications with enzyme replacement
      therapy can improve quality of life.Therefore the primary aim of our project called &quot;BioHunt&quot;
      is the development of a new plasma biomarker for the early and sensitive diagnosis of the
      disease. The secondary aim is the testing for clinical robustness, specificity and long-term
      stability of the biomarker.Within the scope of the study the investigators would like to
      collect in the next 12 months from about 80 patient's plasma and in parallel a simple
      documentation of the clinical data.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hunter disease (mucopolysaccharidosis type II) is a lysosomal storage disease caused by
      deficiency of the enzyme iduronate-2-sulphatase. Deficiency of iduronate sulphatase enzyme
      causes accumulation of the products dermatan sulphate and heparan sulphate in lysosomes
      leading to cell death. Hunter disease can vary from mild to severe, depending on the level of
      enzyme deficiency. Features of the disease include dwarfism, enlarged liver and spleen,
      cardiovascular disorders and deafness.

      Mutations in the IDS gene located at Xq28 causes loss of the iduronidate sulfatase enzyme. A
      pseudogene IDS2 also exists 20 kb from the active IDS gene. The pseudogene IDS2 shares
      homology to exon 2, intron 2, exon 3, intron 3 and intron 7 of the IDS gene.

      Mutations that have been reported in the IDS gene in Hunter patients include gene
      rearrangements caused by recombination with the IDS2 gene (10 per cent patients), deletions
      of certain exons or the entire IDS gene (10 per cent patients) or small mutations including
      insertions, deletions and point mutations (80 per cent patients). To detect all possible
      types of mutations in the IDS gene causing Hunter disease, three procedures are necessary.
      These include Southern blot to look for gene rearrangements, multiplex dosage analysis to
      detect large deletions and DHPLC and sequencing to detect small mutations.

      An accurate biochemical test is available for the diagnosis of Hunter disease consisting of
      the analysis of iduronate-2-sulfatase activity in plasma, leucocytes or cultured cells. This
      test should be considered before molecular analysis is undertaken. Molecular identification
      of the mutation in individuals with a confirmed diagnosis can be used for carrier testing and
      prenatal diagnosis in the family. The biochemical test is not reliable for identifying
      carriers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Development of a new MS-based biomarker for the early and sensitive diagnosis of Hunter disease from plasma and saliva</measure>
    <time_frame>24 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Testing for clinical robustness, specificity and long-term stability of the biomarker</measure>
    <time_frame>24 month</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Lysosomal Storage Diseases</condition>
  <condition>Hunter Disease</condition>
  <condition>Mucopolysaccharidoses</condition>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <description>Patients from the first day of life with Hunter Disease based upon biochemical and/or genetic criteria or who are profoundly suspicious for Hunter disease</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      After inclusion into the study, blood samples will be drawn to identify a deficiency or
      absence of the enzyme iduronate-2-sulfatase (I2S).

      The laboratory examinations of the blood samples will be done exclusively at the Laboratory
      of the Albrecht-Kossel-Institute, University of Rostock. This laboratory offers an existing
      infrastructure, a highly standardized quality of the workflow, a short examination time of
      the samples and a long period of experiences in the assessment of the biological impact of
      mutations and polymorphism.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Hunter Disease based upon biochemical and/or genetic criteria or patients who
        are profoundly suspicious for Hunter disease
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent will be obtained from the patient and their parents/legal guardians
             before any study related procedures.

          -  Patients from the first day of life

          -  The patient has a diagnosis of Hunter syndrome based upon biochemical and/or genetic
             criteria or patients who are profoundly suspicious for Hunter disease

        High-grade suspicion present, if one or more criteria are valid:

          -  Positive family anamnesis for Hunter syndrome

          -  Cognitive regression, learning disability or neurocognitive involvement of
             unrecognized origin

          -  Tonic-clonic seizures without identifiable cause

          -  Eye symptoms without identifiable cause: corneal clouding or glaucoma

          -  Pulmonary symptoms without identifiable cause:

        upper airway obstruction, cardiopulmonary disease

        Exclusion Criteria:

          -  No Informed consent from the patient and their parents/legal guardians before any
             study related procedures.

          -  No diagnosis of Hunter syndrome or no valid criteria for high-grade suspicion of
             Hunter syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arndt Rolfs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rostock, Albrecht-Kossel-Institute for Neuroregeneration</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arndt Rolfs, MD</last_name>
    <phone>+49 381 494</phone>
    <phone_ext>9540</phone_ext>
    <email>arndt.rolfs@med.uni-rostock.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susanne Zielke</last_name>
    <phone>+49 381 494</phone>
    <phone_ext>4739</phone_ext>
    <email>susanne.zielke@med.uni-rostock.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pediatric practice</name>
      <address>
        <city>Oran</city>
        <zip>31000</zip>
        <country>Algeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdelmadjid Benmansour, MD</last_name>
      <email>benmansour_b@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Abdelmadjid Benmansour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre, Servico de Genetica Medica Recruiting</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Giugliani, MD</last_name>
      <phone>+55 51 3316</phone>
      <phone_ext>8011</phone_ext>
      <email>rgiugliani@hcpa.ufrgs.br</email>
    </contact>
    <investigator>
      <last_name>Roberto Giugliani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Giugliani, MD</last_name>
      <phone>+55 51 3359</phone>
      <phone_ext>8011</phone_ext>
      <email>rgiugliani@hcpa.ufrgs.br</email>
    </contact>
    <investigator>
      <last_name>Roberto Giugliani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Pediatric Hospital of Sofia</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radka Tincheva, MD</last_name>
      <phone>+359 889 811</phone>
      <phone_ext>976</phone_ext>
      <email>drrtincheva@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Radka Tincheva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rostck, Albrecht-Kossel-Institute for Neuroregeneration</name>
      <address>
        <city>Rostock</city>
        <zip>18147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Zielke</last_name>
      <phone>+49 381 494</phone>
      <phone_ext>4739</phone_ext>
      <email>susanne.zielke@med.uni-rostock.de</email>
    </contact>
    <investigator>
      <last_name>Arndt Rolfs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aristotle University of Thessaloniki-Ippokration General Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dimitrios Zafeiriou, MD</last_name>
      <email>jeff@med.auth.gr</email>
    </contact>
    <investigator>
      <last_name>Dimitrios Zafeiriou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SOTE Pediatric clinic II, Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <zip>1094</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>György Fekete, MD</last_name>
      <phone>+36 1 218</phone>
      <phone_ext>6844</phone_ext>
      <email>fekete.gyorgy@gyer2.sote.hu</email>
    </contact>
    <investigator>
      <last_name>György Fekete, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NIRMAN, University of Mumbai</name>
      <address>
        <city>Mumbai</city>
        <zip>400705</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anil Jalan, MD</last_name>
      <email>jalananil@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Anil Jalan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research center University of Welfare Science, Medical Genetics Department Sarem Women Hospital</name>
      <address>
        <city>Teheran</city>
        <zip>13969</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yousef Shafeghati, MD</last_name>
      <phone>+98(21) 44 633</phone>
      <phone_ext>283</phone_ext>
      <email>y_shafeghati@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Yousef Shafeghati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Memorial Health Institute, Department of Metabolic Disease</name>
      <address>
        <city>Warsaw</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Tylki-Szymanska, MD</last_name>
      <phone>+48 22 815</phone>
      <phone_ext>7066</phone_ext>
      <email>a.tylki@czd.pl</email>
    </contact>
    <investigator>
      <last_name>Anna Tylki-Szymanska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mother and Child Health Institute of Serbia- Dr. Vukan Cupic</name>
      <address>
        <city>Novi-Beograd</city>
        <zip>11070</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrijan Sarajlija, MD</last_name>
      <email>Adrijan Sarajlija &lt;adrijans2004@yahoo.com&gt;</email>
    </contact>
    <investigator>
      <last_name>Adrijan Sarajlija, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Algeria</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Iran, Islamic Republic of</country>
    <country>Poland</country>
    <country>Serbia</country>
  </location_countries>
  <link>
    <url>http://www.centogene.com/</url>
    <description>Centogene is one of the leading laboratories focusing on genetic testing for rare hereditary disorders.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2011</study_first_submitted>
  <study_first_submitted_qc>April 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2011</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rostock</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Arndt Rolfs</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Biomarker</keyword>
  <keyword>Mucopolysaccharidosis II</keyword>
  <keyword>Lysosomal Storage Diseases</keyword>
  <keyword>Morbus Hunter</keyword>
  <keyword>Mucopolysaccharidoses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Lysosomal Storage Diseases</mesh_term>
    <mesh_term>Mucopolysaccharidosis II</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

